TRIAL DETAIL
GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 06/01/2010 |
Age of Trial (yrs) 14.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PTCH/SMO inhibitor + Gamma Secretase inhibitor |
|||
Strategy: |
Block Hedgehog & Notch pathways |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CDR0000680558, MSKCC-10049 |
|||
Sponsor: |
Memorial Sloan-Kettering Cancer Center, National Cancer Institute |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1275 York Ave |
New York |
NY |
10065 |
USA |